The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a tailored multimodal lifestyle follow-up care program focusing on physical activity, nutritional behavior and psychological processes in adolescent and young adult cancer survivors: The CARE for CAYA multicenter, randomized clinical trial.
 
Simon Elmers
No Relationships to Disclose
 
Julia von Grundherr
No Relationships to Disclose
 
Gabriele Calaminus
No Relationships to Disclose
 
Jorg Faber
Research Funding - Y-mAbs Therapeutics
 
Judith Gebauer
Honoraria - Roche (I)
Consulting or Advisory Role - Roche (I)
Expert Testimony - Roche (I)
Travel, Accommodations, Expenses - BeiGene (I)
 
Miriam Götte
No Relationships to Disclose
 
Inken Hilgendorf
Honoraria - AbbVie; Novartis
Travel, Accommodations, Expenses - BeiGene; Celgene; Janssen-Ciliag; Jazz Pharmaceuticals; medac; Menarini International Foundation
Other Relationship - German Foundation for Young Adults with Cancer
 
Michael Koehler
No Relationships to Disclose
 
Alexander Puzik
No Relationships to Disclose
 
Anette Sander
No Relationships to Disclose
 
Nicole Salzmann
No Relationships to Disclose
 
Lisa Schiffmann
No Relationships to Disclose
 
Sonja Schuster
No Relationships to Disclose
 
Magdalena Sokalska-Duhme
No Relationships to Disclose
 
Alexander Stein
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck KGaA; MSD (Inst); Novartis (Inst); Roche; SERVIER (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck KGaA; Roche; Sanofi; Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
Sarah Dwinger
No Relationships to Disclose
 
Eik Vettorazzi
No Relationships to Disclose
 
Jannike Lisa Salchow
No Relationships to Disclose
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Hexal; I-Med Institute; Medac; Medupdate; Merck KGaA; Merck Sharp Dohme; Roche; Sanofi
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; BioNTech SE; GSO; Janssen-Cilag GmbH; Merck Sharp & Dohme; Oncology Drug Consult (ODC); Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CPT Cellex Patient Treatment (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycostem (Inst); Glycotope GmbH (Inst); immatics (Inst); Incyte (Inst); IO Biotech (Inst); Ipsen (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier/Pfizer (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen-Cilag; Merck Serono; Sanofi
 
Marianne Sinn
Honoraria - Amgen (Inst); AstraZeneca/Hong Kong (Inst); BMS Brazil (Inst); Incyte (Inst); MSD (Inst); Pfizer (Inst); Pierre Fabre (Inst); Servier (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Servier (Inst)